A detailed history of Wells Fargo & Company transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 54,867 shares of ATOS stock, worth $56,513. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,867
Previous 53,065 3.4%
Holding current value
$56,513
Previous $63,000 31.75%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.09 - $1.52 $1,964 - $2,739
1,802 Added 3.4%
54,867 $83,000
Q2 2024

Aug 13, 2024

BUY
$1.03 - $2.1 $53,708 - $109,502
52,144 Added 5661.67%
53,065 $63,000
Q1 2024

May 10, 2024

BUY
$0.8 - $1.89 $8 - $20
11 Added 1.21%
921 $1,000
Q4 2023

Feb 09, 2024

BUY
$0.63 - $0.98 $26 - $41
42 Added 4.84%
910 $0
Q3 2023

Nov 13, 2023

SELL
$0.74 - $1.35 $3,099 - $5,655
-4,189 Reduced 82.84%
868 $0
Q2 2023

Aug 15, 2023

BUY
$0.6 - $1.28 $20 - $43
34 Added 0.68%
5,057 $6,000
Q1 2023

May 12, 2023

BUY
$0.59 - $0.91 $2,485 - $3,832
4,212 Added 519.36%
5,023 $3,000
Q4 2022

Feb 13, 2023

BUY
$0.5 - $1.01 $10 - $21
21 Added 2.66%
811 $0
Q3 2022

Nov 14, 2022

SELL
$0.82 - $1.14 $46 - $64
-57 Reduced 6.73%
790 $1,000
Q2 2022

Aug 12, 2022

SELL
$0.85 - $1.28 $20,477 - $30,836
-24,091 Reduced 96.6%
847 $1,000
Q1 2022

May 16, 2022

SELL
$1.11 - $1.74 $45,192 - $70,842
-40,714 Reduced 62.01%
24,938 $32,000
Q4 2021

Feb 14, 2022

BUY
$1.6 - $3.27 $105,043 - $214,682
65,652 New
65,652 $105,000
Q3 2021

Nov 15, 2021

SELL
$2.89 - $6.4 $3,363 - $7,449
-1,164 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$1.52 - $8.62 $304 - $1,723
200 Added 20.75%
1,164 $7,000
Q1 2021

May 13, 2021

BUY
$0.92 - $4.33 $824 - $3,879
896 Added 1317.65%
964 $2,000
Q4 2020

Feb 09, 2021

BUY
$0.85 - $2.43 $3 - $9
4 Added 6.25%
68 $0
Q3 2020

Nov 05, 2020

BUY
$1.98 - $4.35 $5 - $13
3 Added 4.92%
64 $0
Q1 2020

May 14, 2020

BUY
$0.79 - $1.62 $48 - $98
61 New
61 $0

Others Institutions Holding ATOS

About ATOSSA THERAPEUTICS, INC.


  • Ticker ATOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,624,000
  • Market Cap $130M
  • Description
  • Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...
More about ATOS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.